Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Jasper and its executives made false statements regarding the company's manufacturing controls and the implications for its product, briquilimab [6]. Group 2: Company Performance and Stock Impact - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [7]. - The company announced a halt in the development of briquilimab for asthma and SCID, contradicting previous claims of a strong financial position [7]. - Jasper is implementing cost-cutting measures, including potential restructuring, to extend its financial runway [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues increased the risk of confounding study results and the likelihood of disruptive cost-reduction measures, leading to an overstatement of Jasper's business and financial prospects [5].

Core Viewpoint - Jasper Therapeutics, Inc. is facing a class action lawsuit for investors who purchased securities during the specified class period, following a significant drop in stock price due to issues in a clinical trial [1][3]. Group 1: Class Action Details - The Portnoy Law Firm is advising Jasper investors of a class action on behalf of those who bought securities between November 30, 2023, and July 3, 2025 [1]. - Investors have until November 18, 2025, to file a lead plaintiff motion [1]. Group 2: Stock Price Impact - Following the announcement of issues related to a drug product lot in a clinical trial, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share on July 7, 2025 [3]. Group 3: Clinical Trial Update - On July 7, 2025, Jasper released updated data from its BEACON Phase 1b/2a study, indicating that results from certain dose cohorts were confounded by issues with one drug product lot [3]. - The company is currently investigating the drug product lot and expects to have results in the coming weeks [3]. Group 4: Legal Representation - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific allegations of misleading statements and undisclosed issues affecting their business operations and financial prospects [1]. Quanex Building Products Corporation (NYSE: NX) - Class Period: December 12, 2024 – September 5, 2025 - Allegations include significant underinvestment in tooling and equipment maintenance, leading to degraded conditions and potential significant costs that could delay expected benefits from integration efforts [2]. Jasper Therapeutics, Inc. (NASDAQ: JSPR) - Class Period: November 30, 2023 – July 3, 2025 - Allegations focus on the lack of necessary controls for third-party manufacturers, increasing risks to clinical trial results and overstating the company's financial and product prospects [3]. KBR, Inc. (NYSE: KBR) - Class Period: May 6, 2025 – June 19, 2025 - Allegations state that the company misrepresented the status of its partnership with TRANSCOM, despite known concerns regarding contract fulfillment, leading to misleading statements about business operations [4]. RCI Hospitality Holdings, Inc. (NASDAQ: RICK) - Class Period: December 15, 2021 – September 16, 2025 - Allegations include engagement in tax fraud and bribery to cover up these actions, resulting in understated legal risks and misleading statements about the company's business and operations [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. for alleged violations of federal securities laws, encouraging affected investors to contact them regarding their legal options [1][3]. Group 1: Allegations Against Jasper - The complaint alleges that Jasper and its executives made false or misleading statements and failed to disclose critical information regarding their manufacturing processes and product suitability for clinical trials [3]. - Specific allegations include a lack of necessary controls for third-party manufacturers, which increased the risk of confounding study results and negatively impacted the regulatory and commercial prospects of Jasper's products, particularly briquilimab [3]. - The complaint also suggests that these failures led to overstated business and financial prospects, resulting in materially false public statements by the defendants [3]. Group 2: Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, which affected study results and led to the halting of the ETESIAN Study and the development of briquilimab for asthma and SCID [4]. - Following this announcement, Jasper's stock price dropped by $3.73 per share, or 55.1%, closing at $3.04 per share [4]. Group 3: Legal Proceedings - Investors who purchased Jasper securities between November 30, 2023, and July 3, 2025, are reminded of the November 18, 2025, deadline to seek the role of lead plaintiff in the federal securities class action against the company [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest who is adequate and typical of class members, overseeing the litigation on behalf of the class [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by November 18, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact the clinical and commercial prospects of its products, particularly briquilimab [5]. - The failure to disclose these issues allegedly led to inflated business and financial prospects, resulting in investor damages when the true information became public [5].

Core Viewpoint - Investors in Jasper Therapeutics, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of alleged misrepresentations by the company regarding its manufacturing controls and product prospects [1][3]. Summary by Sections Lawsuit Details - The lawsuit alleges that from November 30, 2023, to July 3, 2025, Jasper Therapeutics failed to disclose critical information, including the lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - This failure is claimed to have increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, particularly briquilimab [3]. - The lawsuit also suggests that the company's business and financial prospects were overstated, and that positive statements made by the defendants were materially misleading [3]. Participation Information - Investors who suffered losses are encouraged to contact the Law Offices of Howard G. Smith before November 18, 2025, to participate in the ongoing class action lawsuit [2][4]. - Individuals do not need to take any immediate action to be part of the class action and may choose to retain counsel or remain absent [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by November 18, 2025 [3][5]. Group 1: Allegations Against Jasper - The complaint alleges that Jasper and its executives made false and misleading statements regarding the company's manufacturing controls and compliance with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, particularly briquilimab [5]. - It is claimed that Jasper's failure to ensure proper manufacturing processes increased the likelihood of cost-reduction measures and overstated the company's business and financial prospects [5]. Group 2: Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [6]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, contradicting previous statements about having a strong financial position [6]. Group 3: Legal Proceedings - Investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Jasper's conduct [8].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 30, 2023, to July 3, 2025, seeking damages for affected investors [1][2]. Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for mast cell-driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and Asthma [3]. - The lead product candidate, briquilimab, is a monoclonal antibody aimed at blocking the stem cell factor (SCF) from signaling through the CD117 (c-Kit) receptor, which is believed to be crucial for mast cell survival [3]. Financial Developments - In 2024, Jasper completed an oversubscribed financing round of $50 million to strengthen its balance sheet and support briquilimab's development, extending its cash runway through the third quarter of 2025 [3]. - Following a press release on July 7, 2025, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share due to concerns over drug lot issues and halted studies [7]. Clinical Trials and Issues - Jasper commenced a Phase 1b/2a clinical study for CSU (BEACON Study) in November 2023 and another for allergic asthma (ETESIAN Study) in December 2024 [3]. - On July 7, 2025, Jasper reported confounding results in the BEACON Study due to issues with a specific drug product lot, leading to the halting of the ETESIAN Study and a pause in SCID development [7][9]. Management and Operational Changes - Following the announcement of the drug lot issues, Jasper revealed a corporate reorganization, including a workforce reduction of approximately 50% and a focus on developing briquilimab for chronic urticaria [9]. - The Chief Medical Officer, Edwin Tucker, is set to depart from his role effective August 1, 2025 [9]. Market Reactions - Analysts reacted to the developments, with BMO Capital Markets downgrading Jasper to market perform and lowering its price target from $6.77 to $4.00, citing potential drug lot issues and uncertainties around dose-response [8].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Jasper Therapeutics, Inc. during the specified Class Period, alleging misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Jasper Therapeutics securities between November 30, 2023, and July 3, 2025 [1]. - The lawsuit claims that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by November 18, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].